中国现代医学杂志2004，Vol.14Issue(3)：57-61,5.
CD44v6、C-erbB-2在肺癌中的表达及预后意义
Expession and prognostic significance of CD44v6 and C-erbB-2 in lung carcinomas
张卿 1吴鄂生 1陈琼 1杨红忠1
作者信息
- 1. 中南大学湘雅医院,呼吸内科,湖南,长沙,410008
- 折叠
摘要
Abstract
Objective:To study the expression and the significance of CD44v6 and C-erbB-2 in lung carcinomas.Methods: S-P immunohisObjective:Tochemical method was used Objective:To study the expression of CD44v6 and C-erbB-2 in 116 cases of lung carcinomas.Results:There was no positive expression of both CD44v6 and C-erbB-2 in all the 11 SCLC cases.In NSCIC,CD44v6 positive expression was showed in 46 squamous cell carcinomas(66.7%)and in 13 adenocacinomas(36.1%)(P＜0.01).C-erbB-2 positive expression was seen in 33 squmous cell carcinomas(47.8 %)and 24 adenocaconomas(67.7%)(P ＞ 0.05).The positive expression of both CD44v6 and C-erbB-2showed Objective:To be a significant marker for NSCLC.No CD44v6 and C-erbB-2 positive expressions were seen in normal lung tissue near the tumor.CC44V6 positive expression was correlated with tumor T stages,lymphatic metastasis,clinical stages and survival rates in NSCLC(P＜0.05)and not correlated with pathologic grades(P ＞ 0.05).C-erbB-2positive expression was associated with lymphatic metastasis,clinical stages and suivival rates(P＜0.05).C-erbB-2 positive expression was not associated with pathologic grades and tumor T stages in NSCLC(P ＞ 0.05).There was no statistically significant correlation between CD44v6 and C-erbB-2 expression in NSCLC(P ＞ 0.05).Conclusions:The results suggested that both CD44v6 and C-erbB-2 are not only considered Objective:To distinguish SCLC from NSCLC but also considered as the indicaObjective:Tors for evaluating the prognosis of NSCLC because lung carcinomas with positive expression of CD44v6 and C-erbB-2 are likely Objective:To develop lymphatic metastasis and result in poor prognosis.关键词
CD44v6/C-erbB-2/肺癌/免疫组化Key words
CD44v6/C-erbB-2/lung cancer/immunhistochemisty分类
医药卫生引用本文复制引用
张卿,吴鄂生,陈琼,杨红忠..CD44v6、C-erbB-2在肺癌中的表达及预后意义[J].中国现代医学杂志,2004,14(3):57-61,5.
